

Canada Anti-Hypertensive Drugs Market by Therapeutic Class (Diuretics, ACE inhibitors, ARBs, Calcium Channel Blockers, Beta Adrenergic Blockers, Renin Inhibitors, Vasodilators, Others), By Type (Primary Hypertension, Secondary Hypertension), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites, Online Drug Stores) and By Region and Competition, Forecast & Opportunities, 2028

<https://marketpublishers.com/r/CCD6DA417D4CEN.html>

Date: October 2023

Pages: 84

Price: US\$ 3,500.00 (Single User License)

ID: CCD6DA417D4CEN

Abstracts

Canada Anti-Hypertensive Drugs Market is anticipated to register a substantial rise over the forecast period, thanks to the growing consumption of junk food, lack of proper healthy and balanced diet, leading sedentary lifestyle along with lack of proper sleep due to irregular work shifts across the region.

Additionally, the increasing prevalence of hypertension is the major factor propelling the growth of the Canada anti-hypertensive drugs market during the forecast period. Also, growing awareness of the complications of high blood pressure and expansion of antihypertensive drug research is expected to increase the demand for anti-hypertensive drugs, thereby boosting the Canada anti-hypertensive drugs market through 2028. The increasing number of initiatives by private and governmental organizations are also expected to increase the demand for anti-hypertensive drugs, supporting the market's growth. For instance, in 2021, 25% of the Canada population under (50-64 year age people) were suffering from hypertension.

According to a report by the Canadian Chronic Disease Surveillance System,

hypertension affects approximately 7.4 million adults in Canada, which is equivalent to 21.6% of the adult population. The prevalence of hypertension increases with age, with approximately 60% of Canadians over the age of 60 being affected by hypertension. In terms of gender, the prevalence of hypertension is similar in men and women. However, women are more likely to be aware of their hypertension and receive treatment for it than men.

Aging Population

The aging population is a significant driver of the growth of the Canada Anti-Hypertensive Drugs market. As people age, the risk of developing hypertension increases, making the condition more prevalent among older adults. According to Statistics Canada, the prevalence of hypertension increases from 8.8% in people aged between 20 and 39 years to 59.1% in people aged between 60 and 79 years. As a result, the demand for anti-hypertensive drugs has been steadily increasing in recent years. Older adults are more likely to have multiple health conditions and take multiple medications, including anti-hypertensive drugs.

Additionally, older adults are more likely to have a higher income, making them more willing and able to pay for prescription medications. Furthermore, the aging population in Canada is expected to continue growing in the coming years, driven by a combination of factors such as increasing life expectancy and declining birth rates. This demographic shift is expected to lead to a further increase in the demand for anti-hypertensive drugs over the next few years.

According to a report by the Canadian Institute for Health Information (CIHI), anti-hypertensive drugs were the second most commonly prescribed medication class in Canada in 2019, accounting for 12% of all prescriptions. The use of hypertensive drugs in Canada is increasing. According to the same CIHI report, the number of prescriptions for antihypertensive drugs increased by 3.7% between 2018 and 2019, which is higher than the overall increase in prescription drug use in Canada during the same period.

Increased Healthcare Spending

Increased healthcare spending is another important driver of the growth of the Canada Anti-Hypertensive Drugs market. The Canadian government has been increasing its healthcare spending to meet the growing demand for medical services, including the treatment of hypertension. As a result of this increased spending, there has been an improvement in the availability and accessibility of healthcare services, including the

availability of anti-hypertensive drugs. This has contributed significantly to the growth of the market, as more people are able to receive the medications, they need to manage their condition.

Moreover, increased healthcare spending has also led to the development of more sophisticated healthcare infrastructure, such as hospitals and clinics, which are better equipped to diagnose and treat hypertension. This has led to an increase in the number of people seeking medical help for this medical condition, aiding the market. The most prescribed classes of antihypertensive drugs in Canada are ACE inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, and diuretics. These medications are used to lower blood pressure and reduce the risk of cardiovascular events in patients with hypertension.

Rise in Lifestyle Diseases

The rise in lifestyle diseases is a key driver of the growth of the Canada Anti-Hypertensive Drugs market. Lifestyle diseases, such as obesity, diabetes, and hypertension, are becoming more prevalent in Canada, driven by several factors, such as sedentary lifestyles, unhealthy diets, and an aging population. As hypertension is a common co-morbidity with other lifestyle diseases, the prevalence of hypertension is also increasing, leading to a surge in the demand for anti-hypertensive drugs. This trend is expected to continue in the coming years, as the prevalence of lifestyle diseases is projected to increase due to changing demographics and lifestyle factors.

Additionally, the rising awareness about the importance of managing hypertension and lifestyle diseases has led to an increase in the number of people seeking medical help for their condition. This has contributed to the growth of the market, as more people are being diagnosed with hypertension and prescribed anti-hypertensive drugs. Pharmaceutical companies operating in the Canada anti-hypertensive drugs market are likely to benefit from this trend in the coming years, as the demand for these drugs is expected to continue to grow. However, they will need to innovate and develop new and more effective drugs to meet the evolving needs of patients with hypertension and lifestyle diseases.

Development of Novel Drugs

The development of new drugs is a critical factor that influences the growth of the Canada anti-hypertensive drugs market. The introduction of new and more effective drugs can drive the demand for anti-hypertensive drugs by providing better treatment

options for patients. Pharmaceutical companies are investing in research and development to create new drugs that offer improved efficacy, safety, and ease of use. New drugs that can control hypertension with fewer side effects, simpler dosing regimens, and longer durations of action are expected to be well-received by patients and healthcare providers. Moreover, the introduction of new drugs can also increase competition among pharmaceutical companies, leading to lower prices and improved access for patients. This can also stimulate innovation and encourage companies to develop more effective drugs.

Another recent development in the market is the increasing usage of telemedicine for the management of hypertension. Telemedicine allows patients to consult with their healthcare provider remotely, which can improve access to care for patients who may have difficulty traveling to a clinic or hospital. Telemedicine can also be a more convenient option for patients and may reduce the burden on healthcare providers. As a result, many healthcare providers are taking up telemedicine to manage hypertension, and this trend is expected to continue to grow in the coming years.

Increased Awareness of Hypertension

The awareness of hypertension is an important driving factor in the Canada anti-hypertensive drugs market. Hypertension is a widespread condition that affects millions of Canadians, and awareness about the importance of managing hypertension has been steadily increasing in recent years. The surge in the awareness of hypertension among consumers has led to more people seeking medical help for their condition, which in turn has contributed to the growth of the market. More people are being diagnosed with hypertension and are prescribed anti-hypertensive drugs as a result of this increased awareness.

In addition to this, the increased awareness of hypertension has led to a greater emphasis on lifestyle modifications, such as exercise and a healthy diet, to manage the condition. This has led to an increase in the number of people taking a proactive approach to managing their hypertension, which has contributed to the growth of the market.

Furthermore, the rise in awareness among consumers regarding hypertension has also led to more research into the condition and the development of new and more effective treatment options. This has helped to stimulate innovation in the Canada anti-hypertensive drugs market and contributed to the development of new drugs.

Market Segmentation

The Canada anti-hypertensive drugs market can be segmented by therapeutic class, type, distribution channel, and region. Based on therapeutic class, the Canada anti-hypertensive drugs market can be segmented into diuretics, ACE inhibitors, ARBs, calcium channel blockers, beta-adrenergic blockers, renin inhibitors, vasodilators, and others. Based on type, Canada anti-hypertensive drugs market can be divided into primary hypertension and secondary hypertension. Based on distribution channel, the anti-hypertensive drugs market in Canada can be segmented into retail pharmacies, hospital pharmacies, and e-commerce websites & online drug stores.

Market Players

Pfizer Canada Inc., Merck Canada Inc., AstraZeneca Canada Inc, Novartis Pharmaceuticals Canada Inc, Sanofi-Aventis Canada Inc., Boehringer Ingelheim (Canada) Ltd., Bristol-Myers Squibb Canada., Takeda Canada Inc., Teva Canada Ltd., and Servier Canada Inc. are some of the leading players operating in the Canada anti-hypertensive drugs market.

Report Scope:

In this report, the Canada anti-hypertensive drugs market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Canada Anti-Hypertensive Drugs Market, By Therapeutic Class:

Diuretics

ACE inhibitors

ARBs

Calcium Channel Blockers

Beta Adrenergic Blockers

Renin Inhibitors

Vasodilators

Others

Canada Anti-Hypertensive Drugs Market, By Type:

Primary Hypertension

Secondary Hypertension

Canada Anti-Hypertensive Drugs Market, By Distribution Channel:

Retail Pharmacy

Hospital Pharmacy

E-commerce Websites & Online Drug Stores

Canada Anti-Hypertensive Drugs Market, By Region:

Ontario Region

Quebec Region

Alberta region

British Columbia region

Saskatchewan and Manitoba region

Rest of Canada

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Canada Anti-Hypertensive Drugs Market.

Available Customizations:

Canada Anti-Hypertensive Drugs Market by Therapeutic Class (Diuretics, ACE inhibitors, ARBs, Calcium Channel B...

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

- 1. Product Overview
 - 1.1. Market Definition
 - 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Types
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends

4. VOICE OF CUSTOMER

5. CANADA ANTI-HYPERTENSIVE DRUGS MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Therapeutic Class (Diuretics, ACE inhibitors, ARBs, Calcium Channel Blockers, Beta Adrenergic Blockers, Renin Inhibitors, Vasodilators, Others)
 - 5.2.2. By Type (Primary Hypertension, Secondary Hypertension)
 - 5.2.3. By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce)

Websites & Online Drug Stores)

5.2.4. By Region (Quebec, Ontario, Alberta, British Columbia, Saskatchewan & Manitoba, Rest of Canada)

5.2.5. By Company (2022)

5.3. Market Map

6. ALBERTA ANTI-HYPERTENSIVE DRUGS MARKET OUTLOOK

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Therapeutic Class

6.2.2. By Type

6.2.3. By Distribution Channel

7. QUEBEC ANTI-HYPERTENSIVE DRUGS MARKET OUTLOOK

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Therapeutic Class

7.2.2. By Type

7.2.3. By Distribution Channel

8. ONTARIO ANTI-HYPERTENSIVE DRUGS MARKET OUTLOOK

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Therapeutic Class

8.2.2. By Type

8.2.3. By Distribution Channel

9. BRITISH COLUMBIA ANTI-HYPERTENSIVE DRUGS MARKET OUTLOOK

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Therapeutic Class

9.2.2. By Type

9.2.3. By Distribution Channel

10. SASKATCHEWAN AND MANITOBA ANTI-HYPERTENSIVE DRUGS MARKET OUTLOOK

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Therapeutic Class

10.2.2. By Type

10.2.3. By Distribution Channel

11. MARKET DYNAMICS

11.1. Drivers

11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition

12.2. Product Development

12.3. Recent Developments

13. POLICY & REGULATORY LANDSCAPE

14. PORTERS FIVE FORCES ANALYSIS

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. CANADA ECONOMIC PROFILE

16. COMPETITIVE LANDSCAPE

- 16.1. Business Overview
- 16.2. Company Snapshot
- 16.3. Products & Services
- 16.4. Financials (As Reported)
- 16.5. Recent Developments
 - 16.5.1. Pfizer Canada Inc
 - 16.5.2. Merck Canada Inc.
 - 16.5.3. AstraZeneca Canada Inc
 - 16.5.4. Novartis Pharmaceuticals Canada Inc
 - 16.5.5. Sanofi-Aventis Canada Inc.
 - 16.5.6. Boehringer Ingelheim (Canada) Ltd.
 - 16.5.7. Bristol-Myers Squibb Canada.
 - 16.5.8. Takeda Canada Inc.
 - 16.5.9. Teva Canada Ltd.
 - 16.5.10. Servier Canada Inc.

17. STRATEGIC RECOMMENDATIONS

18. ABOUT US & DISCLAIMER

I would like to order

Product name: Canada Anti-Hypertensive Drugs Market by Therapeutic Class (Diuretics, ACE inhibitors, ARBs, Calcium Channel Blockers, Beta Adrenergic Blockers, Renin Inhibitors, Vasodilators, Others), By Type (Primary Hypertension, Secondary Hypertension), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce Websites, Online Drug Stores) and By Region and Competition, Forecast & Opportunities, 2028

Product link: <https://marketpublishers.com/r/CCD6DA417D4CEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CCD6DA417D4CEN.html>